News for Verve Therapeutics, Inc. (VERV)

U.S. stocks were lower, with the Dow Jones index falling around 700 points on Monday. Shares of Wolverine World Wide, Inc. WWW rose sharply during Monday's ses...

Several companies in the biotech sector are witnessing a notable increase in search activity, as observed by InvestingChannel. Among them, Third Harmonic Bio (T

Explore VERV's promising gene-editing therapies, including VERVE-102 with a 69% LDL-C reduction. Click here to read my most recent analysis of VERV stock.

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease. In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy.

Editor's Note: This headline has been corrected to reflect that the stock moves occurred on Tuesday U.S. stocks were higher, with the Dow Jones index gaining a...

U.S. stocks were higher, with the Dow Jones index gaining around 50 points on Tuesday. Shares of Netflix, Inc. NFLX rose sharply during Tuesday's session after...

Maine-based Synergy CHC Corp. (SNYR) is up over 139 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Verve Therapeutics (VERV) saw a significant rise in stock price after releasing encouraging early-stage clinical data. The Phase Ib study of VERVE-102 s

Verve Therapeutics (VERV) has received a positive update from H.C. Wainwright, which raised its price target for the company's stock to $25 from the previous $1

Verve Therapeutics (NASDAQ:VERV) stock climbs as gene therapy shows promise in cutting LDL cholesterol by up to 69% in an early-stage trial. Read more here.

Single infusion of VERVE-102 led to dose-dependent decreases in blood PCSK9 and LDL-C, with mean reduction in LDL-C of 53% and a maximum reduction of 69% observ

**media[594184]**

BOSTON, April 11, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease

BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease

**media[586384]**

Shares of several biotech and biopharma names are under pressure on Monday following the resignation of the head of the Food and Drug Administration’s Center for Biologics Evaluation and Research, Peter Marks. RBC Capital says the development is “not good for the biotech industry even beyond vaccines.” Voicing a similar opinion, BMO Capital told investors this morning that it sees the news as a “significant negative” for the biopharma and biotech sectors. “NOT GOOD” FOR BIOTECH SECTOR: RBC Capit

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Verve Therapeutics, Inc. (NASDAQ:VERV) stands against other best gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat […]

We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Verve Therapeutics, Inc.

**media[582591]**